Phase I/II study evaluating the safety, tolerability, and efficacy of sacituzumab govitecan in combination with pegfilgrastim in patients with HER2-negative breast cancer

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2026
This article has no abstract
Epistemonikos ID: 5da1214427f9718f12a759dce55ef3c186694a81
First added on: Oct 10, 2026